You are here

Blocking harmful lung damage during acute exacerbations of chronic obstructive pulmonary disease caused by infections

We propose pioneering studies to prevent the consequences of infection-related exacerbations of chronic obstructive pulmonary disease (COPD) that lead to lung damage and death. We have identified two novel and distinct therapeutic strategies, using the anti-fibrotic drug pirfenidone and an anti-inflammatory STING signalling inhibitor called idronoxil, to avert damaging inflammation and reduce fibrosis in our COPD and infection models. Critically, we have shown that both drugs increase beneficial immune responses to infection, overcoming the major limitation of oral glucocorticoids, the current therapy for COPD exacerbations.
Essential criteria: 
Minimum entry requirements can be found here:
Virus, infection, COPD, lung disease, cell signaling, pirfenidone, steroids
School of Clinical Sciences at Monash Health / Hudson Institute of Medical Research
Available options 
Time commitment 
Top-up scholarship funding available 
Year 1: 
Physical location 
Monash Health Translation Precinct (Monash Medical Centre)
Belinda Thomas

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.